tradmap

EDIT Editas Medicine, Inc.

$2.68 +5.10%

Healthcare · Biological Products, (No Diagnostic Substances)

Editas Medicine, Inc. (EDIT) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $262 million. Shares last traded at $2.68, 40.8% below their 52-week high. Over the past year the stock is up 25.8%. Net profit margin is -395.0%, below the peer median of 6.3%. Revenue grew 25.4% year over year.

Market Cap
$262M
Shares Out
97.9M
EPS (TTM)
$-4.52
P/E Ratio
P/S Ratio
6.48
P/B Ratio
59.53
Dividend / Share
Dividend Yield
52-Week High
$4.53
52-Week Low
$1.66
Volume
276,200
Avg Vol (3m)
121,794.333

Performance

1W
+10.29%
1M
+8.50%
3M
+13.56%
6M
+6.77%
YTD
+30.10%
1Y
+25.82%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
48.17
SMA (50)
$2.94
SMA (200)
$2.66
Price vs SMA50
-9.00%
Price vs SMA200
+0.62%
ATR (14)
$0.25

Financials

Revenue
$41M
Net Income
$-160M
Gross Margin
Operating Margin
-394.9%
Net Margin
-395.0%
Return on Equity
-3631.1%
Return on Assets
-107.2%
Current Ratio
3.22
Debt / Equity
10.70
Revenue Growth (YoY)
+25.4%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.26 2026-05-05
FY 2025 $-1.80 2026-03-09
Q3 2025 $-1.80 2025-11-10
Q2 2025 $-1.54 2025-08-12
Q1 2026 $-0.92 2026-05-05
FY 2025 $-2.88 2026-03-09

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

EDIT vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
6.48 / 5.21 med
+24% premium
Net margin vs peers
-395.0% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.